UBS Maintains a 'Buy' on C.H. Robinson (CHRW); Raises PT & Estimates After Q2 Results
UBS maintains a 'Buy' on C.H. Robinson (Nasdaq: CHRW), raises PT from $71 to $75. UBS analyst says, "While H2/10 will see further y/y pressure on the net revenue margin, the Q2 result should assuage fears and increase investor conviction that the company’s business model is intact and can deliver EPS growth through the cycle." Raises FY10 EPS...
Get Alerted When News Hits On This Stock - FREE!